Furthermore, high expression of Sp4 or ANGPTL4 significantly associated with high risk of glioma (Figure 5E), and contributed to poor survival in GBM patients (Upper and middle panels, Figure 5F–G). Here, ANGPTL4 is linked to glioblastoma.